Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The company’s full-year revenue guidance of $850 million at the midpoint came in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback